A race for a better Duchenne treatment
On Friday, Pfizer presented the first results in humans for gene therapy to treat Duchenne muscular dystrophy. Pfizer's shares were flat on the announcement, but shares in Sarepta Therapeutics, which develop their own treatment, increased 18%. STAT's senior authors Adam Feuerstein and Matthew Herper sat down with some high-caffeinated drinks this morning to discuss the results.
Adam : Hi, Matt, it looks like Sarepta Therapeutics has a more effective and safer gene therapy than Pfizer. It's the big takeaway from the Pfizer presentation on Friday. How do you feel about it?
Unlock this article by subscribing to STAT Plus and enjoy the first 30 days for free!
GOT STARTED
What is it?
STAT Plus is a premium subscription that provides daily market-flowing biopharma coverage and thorough science reporting from a team of decades of industry experience.
What's with?
- Authentic biopharma coverage and analysis, interviews with industry pioneers, policy analysis and first look at groundbreaking laboratories and early stage research
- Online events and panel discussions across the country
- ] Monthly subscriber-only live chat with our journalists and experts in the area
- Discounted tickets for industry events and access to early birds for industry reports
